# Matthieu Coutet

> Matthieu Coutet is a seed investor at Sofinnova Partners backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners)
- Location: Paris, France
- Total investments: 8
- Last investment: May 2026
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/matthieu-coutet-5524955/?ppe=1
- Website: https://x.com/MCoutet
- Facebook: https://www.facebook.com/matthieu.coutet

Matthieu Coutet is a seed investor at Sofinnova Partners in Paris focused on Biotechnology and Health Care. Matthieu Coutet is based out of Paris, Ile-de-France, and is a Board Member of Signadori Bio and also served as a Partner of Sofinnova Partners. Matthieu previously worked at Integra Therapeutics as a Board Member. Matthieu Coutet attended ESIEE Paris.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 38% |
| Health Care | 2 | 25% |
| Genetics | 1 | 13% |
| Life Science | 1 | 13% |
| Therapeutics | 1 | 13% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 38% |
| Series A | 1 | 13% |
| Series B | 1 | 13% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 1 | 13% |
| France | 1 | 13% |
| Belgium | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Signadori Bio | Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. | $13M | Seed | May 06, 2026 |  |
| Signadori Bio | Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. |  |  | Mar 18, 2025 |  |
| Signadori Bio | Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. |  | Seed | Mar 18, 2025 |  |
| AgomAb Therapeutics | AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M | Series C | Oct 11, 2023 |  |
| Integra Therapeutics | Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $5.1M | Seed | Dec 02, 2021 |  |
| AgomAb Therapeutics | AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $74M | Series B | Mar 10, 2021 |  |
| DiogenX | DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes. | $5.1M | Seed | Jun 16, 2020 |  |
| AgomAb Therapeutics | AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $23M | Series A | Apr 03, 2019 |  |

8 of 8 investments shown.

## Co-investors
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 4 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 3 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 3 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 2 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 2 deals together

## About Sofinnova Partners

VC Fund · Paris, France

Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage.The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential topositively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs.It was headquartered in Paris, Ile-de-France in 1972.

5 contacts available at Sofinnova Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alain Tingaud | Venture Partner | https://shizune.co/investors/profile/alain-tingaud |
| Cedric Moreau | Partner | https://shizune.co/investors/profile/cedric-moreau |
| Dominique Verdier | Operations | https://shizune.co/investors/profile/dominique-verdier |
| Edward Kliphuis | Partner | https://shizune.co/investors/profile/edward-kliphuis |
| Jacques Theurillat | Partner, Crossover fund | https://shizune.co/investors/profile/jacques-theurillat-aad0 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Matthieu Coutet invest in?

Matthieu Coutet invests primarily in Biotechnology, Health Care and Genetics startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Matthieu Coutet last invest?

The most recent investment recorded for Matthieu Coutet closed in May 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co